

Correlation of Chemotherapy and Radiation Therapy with Atypical Oral Cellular Changes: A Cytological Study in Cancer Patients

Ibtisam Abdelmoneim¹, Alkhair Abd Almahmoud Idris^{2,*}

ABSTRACT

Background: Oral cancer is a prevalent global health issue, with chemotherapy and radiation therapy commonly used in its treatment. **Methods:** This study aimed to investigate the correlation between oral cytological changes and exposure to chemotherapy and/or radiotherapy. A total of 111 participants were included, consisting of 75 cancer patients undergoing radiotherapy and/or chemotherapy (case group) and 36 healthy individuals (control group). **Results:** Participants' ages ranged from 15 to 70 years. Pap stain analysis revealed that 15.3% of samples exhibited acute inflammation, with 18.7% in the treatment group and 8.3% in healthy individuals. Among chemotherapy dose groups, varying degrees of atypia were observed, with a higher incidence of atypia associated with increased chemotherapy dose. Similarly, radiation therapy doses showed an increase in atypical cellular changes with higher doses. **Conclusions:** Chemotherapy and radiation therapy were found to influence atypical cellular changes and inflammatory infiltration in the oral cavity. The incidence of atypia was observed to increase with higher doses of chemotherapy and radiation therapy.

Key words: Chemotherapy, radiation therapy, oral, atypia

INTRODUCTION

Oral cancer poses a significant global health challenge, impacting diverse populations worldwide¹. Treatment modalities such as chemotherapy and radiation therapy are commonly utilized in managing this condition. Prior research has documented the adverse effects of these treatments, including oral mucositis and disruptions to the normal cell cycle, leading to the development of carcinogenic changes and alterations in epithelial cell regeneration^{2,3}.

This study employs cytological techniques to investigate the impact of short and long durations of cancer treatment on the development of cellular changes in the oral cavity. Specifically, we aim to detect oral cytological changes associated with exposure to chemotherapy and/or radiotherapy. By examining the cellular alterations in oral tissues, we seek to enhance our understanding of the effects of chemotherapy and radiation therapy on the oral mucosa and potentially identify markers of treatment-related changes⁴.

The research is set against the backdrop of the widespread incidence of oral cancer and the importance of elucidating the mechanisms underlying treatment-induced cellular changes⁵⁻⁷. By elucidating the relationship between chemotherapy, radiotherapy, and oral cytological alterations, this study

aims to contribute to the existing body of knowledge on oral disorders among cancer patients, addressing a critical gap in current research.

METHODS

This descriptive analytical cross-sectional study was conducted at the Radiation and Isotope Centre in Khartoum from November 2021 to April 2022. The study aimed to assess the effects of radiotherapy and/or chemotherapy on the oral mucosa using cytological techniques.

The study cohort comprised 111 individuals, with 75 patients undergoing radiotherapy and/or chemotherapy considered as the case group, and 36 apparently healthy individuals serving as the control group. Data collection involved interviews using a pre-tested questionnaire to gather information related to the disease and behavior of the participants.

Cytological techniques were employed to analyze oral cells through the Papanicolaou (PAP) stain method. Smears were fixed with 95% ethanol, stained with Harris Hematoxylin and Eosin Azure, and mounted with DPX for examination. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) software, version 23.0, and STATA 11, including frequency, mean, and chi-square tests.

Ethical approval was obtained from the Khartoum State Ministry of Health Innovation, Development,

¹National University, Sudan

²Ahfad University for Women, Sudan

Correspondence

Alkhair Abd Almahmoud Idris, Ahfad University for Women, Sudan
Email: alkhair20@hotmail.com

History

- Received: Sep 27, 2023
- Accepted: Apr 03, 2024
- Published Online: May 31, 2024

DOI : 10.15419/bmrat.v11i5.887



Copyright

© Biomedpress. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

and Scientific Research Committee in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants, and confidentiality of patient information was strictly maintained throughout the study. Samples were collected with proper protective measures in place to adhere to safety protocols, including COVID-19 precautions. Ethical clearance code: KMOH-RES/06-01-2022.

Table 1: Correlation between cytological diagnosis and treatment doses using Fisher exact test

Variables	Cytological diagnosis			Fisher exact test P-value	
	Benign	Inflammation	Atypia		
Chemotherapy number of doses	One	1	0	0	0.664*
		100.00%	0.00%	0.00%	
	Two	3	0	0	
		100.00%	0.00%	0.00%	
	Three	14	6	3	
		60.90%	26.10%	13.00%	
	Four	7	2	3	
		58.30%	16.70%	25.00%	
	Five	0	1	0	
		0.00%	100.00%	0.00%	
Radiotherapy number of doses	One	1	0	0	0.120*
		100.00%	0.00%	0.00%	
	Two	2	0	1	
		66.70%	0.00%	33.30%	
	Three	17	3	0	
		85.00%	15.00%	0.00%	
	Four	6	2	3	
		54.50%	18.20%	27.30%	

*P value > 0.05 that's considered as statistically insignificant

RESULTS

A total of 111 buccal smear samples were included in the study, with participants' ages ranging from 15 to 70 years. Of these samples, 75 were from patients undergoing radiotherapy and/or chemotherapy, while 36 were from healthy individuals. Pap stain analysis revealed that 15.3% of the samples exhibited acute inflammation, with 18.7% found in the treatment group and 8.3% in healthy individuals (Figure 1).

Analysis of cytological findings based on chemotherapy dose showed varying degrees of atypia, with 3

Table 2: Correlation of cytological atypia in relation to gender & age groups using Fisher exact test

Variables	Cytological Atypia		Fisher exact test P value	
	No	Yes		
Groups	Under treatment	65	10	0.029**
		86.70%	13.30%	
	Healthy individuals	36	0	
		100.00%	0.00%	
Gender	Male	25	5	0.130*
		83.30%	16.70%	
	Female	76	5	
		93.80%	6.20%	
Age groups	15-20 years	8	0	0.142*
		100.00%	0.00%	
	21-30 years	21	0	
		100.00%	0.00%	
	31-40 years	25	2	
		92.60%	7.40%	
	41-50 years	27	3	
		90.00%	10.00%	
51-60 years	15	5		
	75.00%	25.00%		
61-70 years	5	0		
	100.00%	0.00%		

**P-value < 0.05 that's considered as statistically significant.

*P-value > 0.05 that's considered as statistically insignificant.

cases of mild atypia observed in the 3-dose group, 3 cases in the 4-dose group (one patient with moderate atypia and two patients with severe atypia). In the radiation therapy group, no cytological changes were seen after the first dose, while one case of moderate atypia was noted after the second dose and three cases of atypia (one severe, two mild) after the fourth dose. The distribution of study participants by gender showed 27% male and 73% female. Age-wise distribution included 7.2% in the 15-20 age group, 18.9% in the 21-30 age group, 24.3% in the 31-40 age group, 27% in the 41-50 age group, 18% in the 51-60 age group, and 4.5% in the 61-70 age group (Figure 1). Furthermore, correlation analysis between cytological diagnosis and treatment doses revealed significant findings. For instance, chemotherapy dose showed a statistically insignificant correlation with cytological




Figure 1: Distributions of some groups. (A) Distribution of healthy individual according to age groups; (B) Distribution of treatment dose among studied patients; (C) Distribution of chemotherapy treatment dose among studied patients; (D) Distribution of radiotherapy treatment dose among studied patients.

diagnosis ($p > 0.05$), while radiation therapy dose exhibited a statistically significant correlation ($p < 0.05$) with atypical cellular changes (Tables 1, 2, 3 and 4).

Overall, the results indicate a relationship between chemotherapy, radiation therapy, and oral cytological changes, with a higher incidence of atypia associated with increased treatment doses. Additionally, findings suggest variations in cytological diagnosis between the treatment group and healthy individuals.

DISCUSSION

The current study examined 111 samples from patients undergoing chemotherapy and/or radiation therapy in Khartoum state, aged between 15 and 70 years. Of the 111 samples, 75 were from patients undergoing chemotherapy and/or radiation therapy, while 36 were from healthy individuals. The results indicated a mean of 43 with a standard deviation of 12 in cases, and a mean of 35 with a standard deviation of 14 in healthy individuals, yielding a p-value of 0.011.

Our study is supported by several previous reports. For instance, Ahmed and Elemirri's study identified infections and cellular infiltration post-cancer treatment⁸. Minhas *et al.* reported various nuclear atypia in normal buccal mucosa in patients receiving chemoradiotherapy⁹, while Naidu *et al.* in 2004 observed oral mucositis complications associated with radiation therapy and chemotherapy⁹.

In Pap smears, analysis revealed that out of 111 samples, 17 samples (15.3%) from both cases and healthy individuals exhibited acute inflammation, 14 samples (18.7%) were under treatment, and 3 samples (8.3%) were from healthy individuals. Our study findings are

in line with those of Ahmed and Elemirri⁸. Notably, Pap stain serves as an effective method for detecting cellular changes in the buccal mucosa¹⁰.

CONCLUSIONS

Analysis of Papanicolaou (Pap) stain indicates that chemotherapy and radiation therapy have varying effects on atypical cellular changes and inflammatory infiltration in the oral cavity. Specifically, research shows that the incidence of atypia increases with higher doses of chemotherapy and radiation therapy.

ABBREVIATIONS

COVID-19: Coronavirus Disease 2019, **DPX:** Dibutylphthalate Polystyrene Xylene, **KMOH-RES:** Khartoum State Ministry of Health Research Ethics Section, **PAP:** Papanicolaou, **SPSS:** Statistical Package for Social Sciences

ACKNOWLEDGMENTS

None.

AUTHOR'S CONTRIBUTIONS

All authors equally contributed to this work, read and approved the final manuscript.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Data and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Table 3: Correlation between cytological atypia in relation to gender & age treatment groups using Fisher exact test

Variables	Cytological Atypia		Fisher exact test P value	
	No	Yes		
Under treatment gender	Male	25	5	0.508*
		83.30%	16.70%	
	Female	40	5	
		88.90%	11.10%	
Under treatment age groups	15-20 years	5	0	0.389*
		100.00%	0.00%	
	21-30 years	7	0	
		100.00%	0.00%	
	31-40 years	18	2	
		90.00%	10.00%	
	41-50 years	21	3	
		87.50%	12.50%	
Type of treatment	Chemotherapy	34	6	0.742*
		85.00%	15.00%	
	Radiotherapy	31	4	
		88.60%	11.40%	
Total number of dose	One	2	0	0.201*
		100.00%	0.00%	
	Two	5	1	
		83.30%	16.70%	
	Three	40	3	
		93.00%	7.00%	
Four	17	6		
		73.90%	26.10%	
	Five	1	0	
	100.00%	0.00%		

*P-value > 0.05 that's considered as statistically insignificant.

Table 4: Correlation of cytological atypia in relation to treatment doses using Fisher exact test

Variables	Cytological Atypia		Fisher exact test P value	
	No	Yes		
Chemotherapy number of doses	One	1	0	0.743*
		100.00%	0.00%	
	Two	3	0	
		100.00%	0.00%	
	Three	20	3	
		87.00%	13.00%	
Four	9	3		
		75.00%	25.00%	
	Five	1	0	
	100.00%	0.00%		
Radiotherapy number of doses	One	1	0	0.028**
		100.00%	0.00%	
	Two	2	1	
		66.70%	33.30%	
	Three	20	0	
		100.00%	0.00%	
	Four	8	3	
		72.70%	27.30%	

**P-value < 0.05 that's considered as statistically significant.
*P-value > 0.05 that's considered as statistically insignificant.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Ethical approval for this study was obtained from the Khartoum State Ministry of Health Innovation, Development and Scientific Research Committee in accordance with the Declaration of Helsinki Principles, and the agreement was taken from all hospital administrations before taking sample and collecting data. The patient's information were highly secured and not used for other purposes than scientific inquiry. Each participant was asked to sign a written ethical consent form during the interview, before the specimen was taken. The informed ethical consent form was designed and approved by the ethical committee of the Khartoum State Ministry of Health. Ethical clearance code number: KMOH-RES/06-01-2022 Date: 11/12/2022.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Mummudi N, Agarwal JP, Chatterjee S, Mallick I, Ghosh-Laskar S. Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities. *Clinical Oncology (Royal College of Radiologists (Great Britain))*. 2019;31(8):520–8. PMID: 31174947. Available from: <https://doi.org/10.1016/j.clon.2019.05.013>.
2. National Institute of Dental and Craniofacial Research (NIDCR). <https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-dental-craniofacial-research-nidcr>;
3. Ibrahim EM, al Mulhim FA. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. *Medical Oncology (Northwood, London, England)*. 1997;14(1):47–51. PMID: 9232612. Available from: <https://doi.org/10.1007/BF02990946>.
4. Johnson NW, Ranasinghe AW, Warnakulasuriya KA. Potentially malignant lesions and conditions of the mouth and oropharynx: natural history cellular and molecular markers of risk. *European Journal of Cancer Prevention*. 1993;2:31–51. PMID: 8364369. Available from: <https://doi.org/10.1097/00008469-199306000-00007>.
5. Mehrotra R, Goel N, Singh M, Kumar D. Radiation-related cytological changes in oral malignant cells. *Indian Journal of Pathology & Microbiology*. 2004;47(3):343–7. PMID: 16295420.
6. Mehrotra R, Gupta A. Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions. *Molecular cancer*. 2006;5(11). Available from: <https://doi.org/10.1186/1476-4598-5-11>.
7. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. *Nature Clinical Practice Oncology*. 2007;4(3):156–71. PMID: 17327856. Available from: <https://doi.org/10.1038/nconp0750>.
8. Ahmed HG, Elemirri DA. Assessment of oral cytological changes associated with exposure to chemotherapy and/or radiotherapy. *CytoJournal*. 2009;6:8. PMID: 19495410. Available from: <https://doi.org/10.4103/1742-6413.51332>.
9. Minhas S, Kashif M, Altaf W, Afzal N, Nagi AH. Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma. *Cancer Biology & Medicine*. 2017;14(2):176–82. PMID: 28607808. Available from: <https://doi.org/10.20892/j.issn.2095-3941.2016.0096>.
10. Ahmad HG, Ebnoof SG, Hussin MO, Gbreel AY. Oral epithelial atypical changes in apparently healthy oral mucosa exposed oral mucosa to smoking, alcohol, peppers and hot meals, using the AgNOR and papanicolaou staining techniques. *Diagnostic Cytopathology*. 2009;38(7):489–95. Available from: <https://doi.org/10.1002/dc.21224>.